Human C5aR knock-in mice facilitate the production and assessment of anti-inflammatory monoclonal antibodies

Nature Biotechnology

Volumn 24, Issue 10, 2006, Pages 1279-1284

  Lee, Hyun ^a   Zahra, David ^a,b   Vogelzang, Alexis ^a,b   Newton, Rebecca ^a   Thatcher, Jenny ^a   Quan, Annie ^a   So, Trina ^a   Zwirner, Jörg ^c   Koentgen, Frank ^d   Padkjær, Søren B ^e   Mackay, Fabienne ^a   Whitfeld, Peter L ^b   Mackay, Charles R ^a,b  

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b G2 Inflammation Pty Ltd   (Australia)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

^d Ozgene Pty Ltd   (Australia)

^e NOVO NORDISK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTAGONISTS; HUMAN THERAPEUTIC; MURINE K/BXN MODEL; POTENCY;

CELL CULTURE; DRUG THERAPY; PHYSIOLOGICAL MODELS;

MONOCLONAL ANTIBODIES;

ANTIINFLAMMATORY AGENT; COMPLEMENT COMPONENT C5A; COMPLEMENT COMPONENT C5A RECEPTOR; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY AFFINITY; ANTIBODY PRODUCTION; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; ARTICLE; CELL MIGRATION; CONTROLLED STUDY; DRUG POTENCY; DRUG TARGETING; EMBRYO; FEMALE; HUMAN; HUMAN CELL; IMMUNIZATION; IMMUNOTHERAPY; IN VITRO STUDY; KNOCKIN MOUSE; KNOCKOUT MOUSE; LOW DRUG DOSE; MALE; MEDIATOR RELEASE; MOUSE; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; SIGNAL TRANSDUCTION;

ANIMALS; ANTIBODIES, MONOCLONAL; EPITOPES; HUMANS; INFLAMMATION; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; NEUTROPHILS; RECEPTORS, COMPLEMENT;

MURINAE;

EID: 33749840453     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt1248     Document Type: Article

References (30)

1. Gerard, C. & Gerard, N.P. C5A anaphylatoxin and its seven transmembrane-segment receptor. Annu. Rev. Immunol. 12, 775-808 (1994).
2. Mackay, C.R. Chemokines: immunology's high impact factors. Nat. Immunol. 2, 95-101 (2001).
3. von Andrian, U.H. & Mackay, C.R. T-cell function and migration. Two sides of the same coin. N. Engl. J. Med. 343, 1020-1034 (2000).
4. Luster, A.D., Alon, R. & von Andrian, U.H. Immune cell migration in inflammation: present and future therapeutic targets. Nat. Immunol. 6, 1182-1190 (2005).
5. Heath, H. et al. Chemokine receptor usage by human eosinophils. The importance of CCR3 demonstrated using an antagonistic monoclonal antibody. J. Clin. Invest. 99, 178-184 (1997).
6. Guo, R.F. & Ward, P.A. Role of C5a in inflammatory responses. Annu. Rev. Immunol. 23, 821-852 (2005).
7. Riedemann, N.C., Guo, R.F. & Ward, P.A. The enigma of sepsis. J. Clin. Invest. 112, 460-467 (2003).
8. Ji, H. et al. Arthritis critically dependent on innate immune system players. Immunity 16, 157-168 (2002).
9. Gerard, C. & Gerard, N.P. The pro-inflammatory seven-transmembrane segment receptors of the leukocyte. Curr. Opin. Immunol. 6, 140-145 (1994).
10. Sumichika, H. C5a receptor antagonists for the treatment of inflammation. Curr. Opin. Investig. Drugs 5, 505-510 (2004).
11. Carter, P.J. Potent antibody therapeutics by design. Nat. Rev. Immunol. 6, 343-357 (2006).
12. Reichert, J.M., Rosensweig, C.J., Faden, L.B. & Dewitz, M.C. Monoclonal antibody successes in the clinic. Nat. Biotechnol. 23, 1073-1078 (2005).
13. Hopkin, M. Can super-antibody drugs be tamed? Nature 440, 855-856 (2006).
14. Qin, S. et al. The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J. Clin. Invest. 101, 746-754 (1998).
15. Wu, L. et al. Interaction of chemokine receptor CCR5 with its ligands: multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding. J. Exp. Med. 186, 1373-1381 (1997).
16. Gerard, N.P. et al. An anti-inflammatory function for the complement anaphylatoxin C5a binding protein, C5L2. J. Biol. Chem. 280, 39677-39680 (2005).
17. Soruri, A., Kim, S., Kiafard, Z. & Zwirner, J. Characterization of C5aR expression on murine myeloid and lymphoid cells by the use of a novel monoclonal antibody. Immunol. Lett. 88, 47-52 (2003).
18. Gerard, C. et al. Structural diversity in the extracellular faces of peptidergic G-protein-coupled receptors. Molecular cloning of the mouse C5a anaphylatoxin receptor. J. Immunol. 149, 2600-2606 (1992).
19. Siciliano, S.J. et al. Two-site binding of C5a by its receptor: an alternative binding paradigm for G protein-coupled receptors. Proc. Natl. Acad. Sci. USA 91, 1214-1218 (1994).
20. 2-terminal domain. J. Immunol. 151, 3785-3794 (1993).
21. Farzan, M. et al. Sulfated tyrosines contribute to the formation of the C5a docking site of the human C5a anaphylatoxin receptor. J. Exp. Med. 193, 1059-1066 (2001).
22. Shevchuk, N.A. et al. Construction of long DNA molecules using long PCR-based fusion of several fragments simultaneously. Nucleic Acids Res. 32, e19 (2004).
23. Klco, J.M., Wiegand, C.B., Narzinski, K. & Baranski, T.J. Essential role for the second extracellular loop in C5a receptor activation. Nat. Struct. Mol. Biol. 12, 320-326 (2005).
24. Grant, E.P. et al. Essential role for the C5a receptor in regulating the effector phase of synovial infiltration and joint destruction in experimental arthritis. J. Exp. Med. 196, 1461-1471 (2002).
25. Korganow, A.S. et al. From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins. Immunity 10, 451-461 (1999).
26. Wang, Y., Rollins, S.A., Madri, J.A. & Matis, L.A. Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease. Proc. Natl. Acad. Sci. USA 92, 8955-8959 (1995).
27. Wipke, B. & Allen, P. Essential role of neutrophils in the initiation and progression of a murine model of rheumatoid arthritis. J. Immunol. 167, 1601-1608 (2001).
28. Kontgen, F., Suss, G., Stewart, C., Steinmetz, M. & Bluethmann, H. Targeted disruption of the MHC class II Aa gene in C57BL/6 mice. Int. Immunol. 5, 957-964 (1993).
29. Campbell, J.J., Qin, S., Bacon, K.B., Mackay, C.R. & Butcher, E.C. Biology of chemokine and classical chemoattractant receptors: differential requirements for adhesion-triggering versus chemotactic responses in lymphoid cells. J. Cell Biol. 134, 255-266 (1996).
30. Lee, D.M. et al. Mast cells: a cellular link between autoantibodies and inflammatory arthritis. Science 297, 1689-1692 (2002).